Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care.
The treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has evolved rapidly in the past decade with the approval of several life-prolonging therapies including docetaxel chemotherapy and multiple androgen receptor pathway inhibitors (ARPI) in combination with androgen depriv...
| Publicado en: | Current Oncology Vol. 30; no. 4; pp. 4365 - 4379 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Apr2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |